FDA ta ba da izini na mobocertinib don ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta tare da maye gurbin shigarwar EGFR 20.

Satumba 2021: FDA ta ba da hanzarin amincewa ga mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) ga tsofaffi marasa lafiya waɗanda ke da ci gaba na gida ko ƙananan ƙwayar ƙwayar ƙwayar huhu (NSCLC) waɗanda ke da EGFR exon 20 insertio ..

Saukewa: KRAS G12C, Kit ɗin KRAS RGQ PCR, RAS GTPase, sotorasib

Sotorasib ya karɓi hanzari amincewa daga FDA don KRAS G12C mutant NSCLC

Agusta 2021: FDA ta ba da hanzarin amincewa ga sotorasib (Lumakras TM, Amgen, Inc.), mai hanawa dangin RAS GTPase, don manyan marasa lafiya tare da KRAS G12C sun canza ci gaba na cikin gida ko ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta (NSCLC) w ..

ALK, B7461006, crizotinib, Lorbrena, lolatinib, NCT03052608, Pfizer, Ventana ALK, Tsarin Kiwon Lafiya na Ventana

FDA ta amince da Lorlatinib don kula da metastatic ALK-positive NSCLC.

Agusta 2021: Lorlatinib (Lorbrena, Pfizer Inc.) ya karɓi amincewar FDA ta yau da kullun ga marasa lafiya da ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta (NSCLC) wanda ciwace-yawacen ta su ne anaplastic lymphoma kinase (ALK)-tabbatacce, kamar yadda FDA-app ta ƙaddara.

anaplastic lymphoma kinase, B7461006, CDx Assay, Abinci da Drug Administration, Lorbrena, lolatinib, NCT03052608, Bayanin NSCLC, Pfizer, Ventana ALK, Tsarin Kiwon Lafiya na Ventana

FDA ta amince da Lorlatinib don kula da metastatic ALK-positive NSCLC

Agusta 2021: Lorlatinib (Lorbrena, Pfizer Inc.) ya karɓi amincewar FDA ta yau da kullun ga marasa lafiya da ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta (NSCLC) wanda ciwace-yawacen ta su ne anaplastic lymphoma kinase (ALK)-tabbatacce, kamar yadda FDA-app ta ƙaddara.

cemiplimab-rwlc, Egfr, FDA, Abinci da Drug Administration, NCT03088540, Bayanin NSCLC, Bayanan PD-L1

FDA ta amince da Cemiplimab-rwlc don cutar kansar huhu ba ƙananan ƙwayar cuta tare da babban magana PD-L1

Agusta 2021: FDA ta amince da cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) don kula da layin farko na marasa lafiya da ke fama da ciwon daji na huhu (NSCLC) (wanda ya ci gaba a cikin gida wanda ba ɗan takara bane na tiyata ..

FDA, Saukewa: KRAS G12C, Lumakras, Bayanin NSCLC, sotorasib

FDA ta amince da maganin farko da aka yi niyya don maye gurbin cutar kansar huhu wanda a baya ake tunanin ba zai iya jurewa da magani ba

20 ga Agusta, 2021: Kwanan baya a watan Mayu, 2021 Lumakras (sotorasib) Hukumar Abinci da Magunguna ta Amurka ta amince da ita a matsayin magani na farko ga tsofaffi marasa lafiya da ƙananan ƙwayoyin cutar huhu na huhu waɗanda suka sha aƙalla tsarin farko ɗaya.

sigari

Fiye da kashi 12% na sababbin cututtukan da suka kamu da cutar sankarar huhu sabo sun sha sigari - binciken ya nuna

Yuli 7th 2021: Shan taba sigari shine babban dalilin sankara na huhu, yana ɗaukar sama da 80% na duk waɗanda ke mutuwa daga cutar. Mutanen da ba su shan taba, duk da haka, suna iya kamuwa da cutar kansa ta huhu. A cewar wani sabon binciken, arou ..

Juriyar ƙwayoyi a cikin ƙananan ƙwayoyin cuta na huhu

Abin da za a yi game da juriya da ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin cuta, da keɓaɓɓen ƙwayoyin cuta da ƙwayoyin cuta, kuna so ku sani a nanLankarar huhu ita ce kansar da ke da mafi yawan cututtuka da mace-mace a cikin China. Kimanin mutane miliyan 1.6 ke mutuwa daga wannan cutar kowace shekara ..

PD-1 da PD-l1 maganin kansar huhu

Lung cancer immunotherapy, lung cancer immunotherapy, lung cancer PD-1 treatment, and lung cancer PD-L1 treatment are all you want to know. In the past two years, immune checkpoint inhibitors have undoubtedly been one of the most..

Brigatinib don ALK-tabbatacce crizotinib mai juriya mara ƙananan ƙananan ciwon huhu na huhu

Malaman Dong-Wan Kim daga Asibitin Jami'ar Seoul na Koriya ta Kudu za su ba da rahoton baka game da taro na musamman na cutar kansar huhu mara ƙanƙanta a wurin taron shekara-shekara karo na 52 na ƙungiyar jama'ar Amurka ta Oncolo.